| Autor: |
Sara Marsal Barril, Mª Auxiliadora Martin-Martinez, Francisco Javier Blanco-Garcia, Antonio Fernández-Nebro, Rosario García de Vicuña, Jesús Tornero-Molina, Fernando Sánchez-Alonso, Marta Novella-Navarro, Alejandro Escudero-Contreras, Juan José Alegre-Sancho, Ana Urruticoechea-Arana, Maria Sagrario Bustabad-Reyes, Pilar Trenor-Larraz, Trinidad Pérez-Sandoval, Maria Isabel Tevar-Sánchez, Jesús T. Sánchez-Costa, Enrique Raya-Álvarez |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Reumatologia clinica. 18(10) |
| ISSN: |
2173-5743 |
| Popis: |
To evaluate the effectiveness and safety of tocilizumab (TCZ) monotherapy in biologic-naïve patients with rheumatoid arthritis (RA) versus patients with previous biologic exposure in a real-world setting.Non-controlled clinical-trial, 32-week prospective multicenter study including RA patients with moderate-severe disease activity starting TCZ in monotherapy who had a prior inadequate response or were intolerant to methotrexate (MTX). Effectiveness according to EULAR response evaluated at 24-week and safety at 32-weekwere assessed.Of the 93 were enrolled of whom 84 (90%) were eligible for the effectiveness analysis. Biologic-naïve patients (n=46, 54.8%) were younger (51.5 versus 57.9) with shorter disease duration (6.4 versus 13.3) but presented similar comorbidities in comparison with non-naïve patients. DAS28 remission was achieved in a higher percentage in the group of patients with prior biological treatment. 89 adverse events (AE) were recorded in 50 patients, most of them non-serious AE (non-SAE) (86.3%).In a real world setting, TCZ exhibit similar effectiveness and safety in monotherapy in patients with RA regardless previous exposure to other biologic therapies. This study provides additional and valuable real-world findings on the use of TCZ in patients with RA. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect